Results 191 to 200 of about 26,436 (212)

Resistance of Lenvatinib in Hepatocellular Carcinoma

Current Cancer Drug Targets, 2022
Qiuran Xu, Junjun Zhao
exaly  

Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review

International Immunopharmacology, 2021
Dun-Chang Mo, Peng-Hui Luo, Han-Lei Wang
exaly  

Lenvatinib

Reactions Weekly, 2018
  +5 more sources

Lenvatinib

Reactions Weekly, 2017
  +4 more sources

Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy

Biochimica Et Biophysica Acta: Reviews on Cancer, 2020
Yan Zhao
exaly  

Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice

Cancer Immunology, Immunotherapy, 2021
Jian-Hong Zhong, Wen-Feng Gong, Ping-Ping Guo   +2 more
exaly  

METTL3-mA-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma

Cancer Letters, 2023
Jihui Huo
exaly  

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

European Journal of Cancer, 2023
Marianna Silletta, Angelo Della Corte, Fabio Piscaglia   +2 more
exaly  

Lenvatinib

Reactions Weekly, 2016
openaire   +1 more source

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma

Therapeutic Advances in Medical Oncology, 2021
Yao-Jun Zhang, Qijiong Li, Ming Shi
exaly